DIVISLAB.NS Profit & Loss
Divi's Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:45
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹7,767.51 Cr. | ₹7,845.00 Cr. | ₹9,360.00 Cr. | ₹10,560.00 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹344.66 Cr. | ₹339.00 Cr. | ₹352.00 Cr. | ₹507.00 Cr. | OtherIncome |
| Total Income | ₹8,112.17 Cr. | ₹8,184.00 Cr. | ₹9,712.00 Cr. | ₹11,067.00 Cr. | Income |
| Cost of Materials Consumed | ₹3,008.36 Cr. | ₹3,232.00 Cr. | ₹3,821.00 Cr. | ₹4,378.00 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹22.33 Cr. | ₹6.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹23.03 Cr. | ₹-109.00 Cr. | ₹-96.00 Cr. | ₹-285.00 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹975.02 Cr. | ₹1,094.00 Cr. | ₹1,243.00 Cr. | ₹1,442.00 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹0.67 Cr. | ₹3.00 Cr. | ₹2.00 Cr. | ₹23.00 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹343.18 Cr. | ₹378.00 Cr. | ₹402.00 Cr. | ₹463.00 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹1,370.95 Cr. | ₹1,417.00 Cr. | ₹1,424.00 Cr. | ₹1,584.00 Cr. | OtherExpenses |
| Total Expenses | ₹5,743.54 Cr. | ₹6,021.00 Cr. | ₹6,796.00 Cr. | ₹7,605.00 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹2,368.63 Cr. | ₹2,163.00 Cr. | ₹2,916.00 Cr. | ₹3,462.00 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹-74.00 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹2,368.63 Cr. | ₹2,163.00 Cr. | ₹2,916.00 Cr. | ₹3,388.00 Cr. | ProfitBeforeTax |
| Tax Expense | ₹545.25 Cr. | ₹563.00 Cr. | ₹725.00 Cr. | ₹820.00 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹1,823.38 Cr. | ₹1,600.00 Cr. | ₹2,191.00 Cr. | ₹2,568.00 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹1,823.38 Cr. | ₹1,600.00 Cr. | ₹2,191.00 Cr. | ₹2,568.00 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹68.69 | ₹60.27 | ₹82.53 | ₹96.75 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹68.69 | ₹60.27 | ₹82.53 | ₹96.75 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from DIVISLAB.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).